Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
https://doi.org/10.17650/1818-8346-2014-9-1-6-10
Abstract
Therapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients, achieved pre-transplant complete or almost complete remission and received one auto-HSCT was 40 % compared with 18 % in patients who achieved only a partial response (p = 0.07). 10-years overall survival in patients received tandem auto-HSCT was
40 % compared with 20 % in patients after one auto-HSCT. Statistically significant differences in 5-years progression-free survival (34 % after tandem auto-HSCT vs. 22 % after one auto-HSCT; p = 0.004) also were revealed.
About the Authors
Ye. I. Darskaya
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
N. E. Marami-Zonuzi
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Yu. S. Osipov
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
M. A. Estrina
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Ye. V. Babenko
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
V. N. Vavilov
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
B. V. Afanasiev
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Rajkumar S.V., Blood E., Vesole D.H. et al. Phase III clinical trial of thalidomide plus dexamethasone ompared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative OncologyGroup. J Clin Oncol 2006;24:431–6.
2. Rajkumar S.V., Hayman S., Gertz M.A. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319–23.
3. Rajkumar S.V., Hayman S.R., Lacy M.Q. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–3.
4. Richardson P.G., Sonneveld P., Schuster M.W. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.
5. Lacy M.Q., Hayman S.R., Gertz M.A. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.
6. Weber D.M., Chen C., Niesvizky R. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.
7. Dimopoulos M., Spencer A., Attal M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.
8. Rajkumar S.V., Jacobus S., Callander N.S. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
9. Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.
10. Brenner H., Gondos A., Pulte D. Recent ajor improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–6.
11. Raab M.S., Podar K., Breitkreutz I. et al. Multiple myeloma. Lancet 2009;374(9686):324–39.
12. Harousseau J., Attal M., Leleu X. et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–505.
13. Barlogie B., Jagannath S., Vesole D.H. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–93.
14. Attal M ., Harousseau J.L., Facon T. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. InterGroupe Francophone du Myélome. N Engl J Med 2003;349:2495–502.
15. Sonnevel d P., Schmidt-Wolf I.G., van der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMGHD4 trial. J Clin Oncol 2012;30(24):2946–55.
16. Attal M., Lauwers-Cances V., Marit G. et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91.
Review
For citations:
Darskaya Ye.I., Marami-Zonuzi N.E., Osipov Yu.S., Estrina M.A., Babenko Ye.V., Vavilov V.N., Afanasiev B.V. Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy. Oncohematology. 2014;9(1):6-10. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-1-6-10
Views:
9981
Email this article 